Abstract

bit.bio discovery has developed a CRISPR perturbation screening platform to query human biology within the context of industry-defining induced pluripotent stem cell (iPSC) derived models. The screening platform is applicable across a wide range of biological questions and disease areas due to the quality and physiological relevance of the models and the inherent rigor of the genomic screening approach. Here, we utilise our iPSC derived ioGlutamatergic neurons and the CROP-Seq workflow to perturb genes known to be associated with various neurodegenerative diseases. This study provides proof-of-concept that functional genomic screening in iPSC derived models can be performed at both iPSC stage and following forward programming in differentiated cells. Our data highlights the importance of timing and differentiation state when performing screens for disease modelling and drug discovery.